Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

OTC Awards

- PMLiVE

FDA lifts hold on Gilead’s clinical trials for leukaemia

Following a review of the safety data, enrolment can be resumed for the MDS and AML clinical trials

- PMLiVE

AbbVie’s Rinvoq accepted by SMC for atopic dermatitis

Scotland is the first nation in the UK to approve NHS access for the drug

- PMLiVE

Pfizer appoints David Denton as chief financial officer and executive vice president

Denton’s appointment follows the departure of Frank D’Amelio, the current CFO and executive vice president

Launch excellence

In the April edition of PME, Cheryl Harrison Doyle, Global Asset Strategy Director at Lucid Group discusses the need to take a more considered, outcomes-led approach when launching new medicines...

Lucid Group Communications Limited

Case Study: Reducing Travel-Related Emissions and Costs Through Virtual Events

In early 2021, due to COVID-19-related safety concerns and travel and social distancing restrictions, our client needed help to “virtualize” their nationwide, multi-day, multi-business unit internal event with 375 attendees....

Impetus Digital

- PMLiVE

Value add: using digital engagement metrics to optimise and drive salesforce effectiveness

By Simon Grime

- PMLiVE

EIT Health launches the WorkInHealth Foundation

The new initiative aims to find new talent to meet increasing digital demands

Claire Gillis appointed to newly created role of CEO of VMLY&R HEALTH

The company has also created an additional four new leadership roles

Meet The Lucid Group Talent Team

Meet our talent team, they're here to help and transform your career.We have some exciting roles at all levels in account management and medical writing.If you choose to take your...

Lucid Group Communications Limited

Celebrating the new UK rare diseases framework

Dice's take on the importance of the rare diseases framework

Dice Medical Communications

- PMLiVE

Pfizer and viral infection specialist ReViral agree on $525m deal

According to the deal, Pfizer will acquire ReViral for a total of up to $525m

- PMLiVE

Gavi, MedAccess and the Open Society Foundations partner to support COVAX

COVAX has delivered more than 1.4 billion COVID-19 vaccines to 145 countries and territories

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links